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Protein tyrosine phosphatases have long been considered key regulators of biological processes and are there-
fore implicated in the origins of various human diseases. Heterozygosity, mutations, deletions, and the complete
loss of some of these enzymes have been reported to cause neurodegenerative diseases, autoimmune syndromes,
genetic disorders, metabolic diseases, cancers, and many other physiological imbalances. Vaccinia H1-related phos-
phatase, also known as dual-specificity phosphatase 3, is a protein tyrosine phosphatase enzyme that regulates the
phosphorylation of the mitogen-activated protein kinase signaling pathway, a central mediator of a diver-
sity of biological responses. It has been suggested that vaccinia H1-related phosphatase can act as a tumor sup-
pressor or tumor-promoting phosphatase in different cancers. Furthermore, emerging evidence suggests that this
enzyme has many other biological functions, such as roles in immune responses, thrombosis, hemostasis, angio-
genesis, and genomic stability, and this broad spectrum of vaccinia H1-related phosphatase activity is likely the result
of its diversity of substrates. Hence, fully identifying and characterizing these substrate-phosphatase interactions will
facilitate the identification of pharmacological inhibitors of vaccinia H1-related phosphatase that can be evaluated
in clinical trials. In this review, we describe the biological processes mediated by vaccinia H1-related phosphatase,
especially those related to genomic stability. We also focus on validated substrates and signaling circuitry with clinical
relevance in human diseases, particularly oncogenesis.
KEYWORDS: Protein tyrosine phosphatase (PTP); Vaccinia H1-related phosphatase (VHR); Dual-specificity
phosphatase 3 (DUSP3); Mitogen-activated protein kinase (MAPK).
Protein Tyrosine Phosphatases, Dual-Specificity
Phosphatases, and VHR/DUSP3
Protein tyrosine phosphatases (PTPs) are highly catalyti-
cally active enzymes that counteract the actions of protein
tyrosine kinases (PTKs). This pair of families has different
evolutionary origins. PTPs are organized into four classes
(I to IV) based on the presence of either a cysteine or an
aspartate in the catalytic site (1-3).
Class I PTPs are subdivided into classical tyrosine phos-
phatases and non-classical or dual-specificity tyrosine phos-
phatases (DUSPs), the latter of which are a less common
group of enzymes that dephosphorylate both tyrosine and
serine/threonine residues (1). DUSPs comprise the largest
(61 proteins) and most diversified group of non-classical
PTPs. A highly conserved consensus or signature sequence,
HC(X)5R, is present in the catalytic domain of both classical
and non-classical tyrosine phosphatases (1,4). The catalytic
mechanisms by which PTPs and DUSPs exert their effects are
quite evolutionarily conserved and involve substrate hydro-
lysis and the formation of a stable phosphoryl-cysteine
intermediate (5-7).
The atypical dual-specificity phosphatases (ADUSPs)
include 19 proteins and were discovered in the last 10 years.
Most of these proteins are small (o27 kDa and/oro250 aa),
and because they have the ability to dephosphorylate Tyr
and Ser/Thr residues, they can act on substrates, such as
mRNAs, lipids, and glycogen (5,8).
ADUSPs possess the consensus catalytic domain of PTPs
and typical DUSPs, and this domain is responsible for their
phosphatase activity. However, ADUSPs also possess regu-
latory and/or recognition sequences at their C- and N-termini,
and these surround the catalytic active site (9,10). ADUSPs
do not have the CH2 (Cdc25 homology 2) domain that is
normally associated with typical DUSPs (5,8) and is res-
ponsible for their specificity for mitogen-activated protein
kinases (MAPKs) (8,11,12). However, even without these
recognition sequences, some ADUSPs are capable of dephos-
phorylating ERK, JNK, and p38 (5,8).
This is the case for Vaccinia H1-related phosphatase (VHR)
or dual-specificity phosphatase 3 (DUSP3), which was first
identified in higher eukaryotes and was the first phospha-
tase to be crystallized (13,14). It weighs approximately 21 kDa
and contains 185 residues, including PTP domains with the
HC(X)5R consensus sequence. The VHR crystal structure
includes a catalytic site that is 6 Å deep, which is shallower
than all other classic PTPs (9 Å deep), and this may explain
the substrate diversity observed among this enzyme (5,13,15).
VHR is constitutively active, is widely expressed in severalDOI: 10.6061/clinics/2018/e466s
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tissues, and can localize to either the nucleus or cytosol, with
its localization important to its various functions (16,17).
Among the biological roles attributed to VHR (discussed
later) is its ability to control the cell cycle, which affects
cell proliferation. This makes the study of VHR important for
developing therapeutic strategies for different types of cancers.
VHR behaves similar to a MAPK phosphatase (MKP or a
typical DUSP) in that it can dephosphorylate ERK, JNK, and
p38 (16,18-22) via a CH2-independent catalytic mechanism.
VHR also displays increased catalytic activity in the presence
of the serine/threonine kinase VRK3 and the tyrosine kinases
Zap70 and Tyk2, all of which bind and/or chemically modify
VHR to enhance its activity (19,22,23). These VHR-related regu-
latory mechanisms warrant further investigation as a potential
therapeutic targets for controlling tumorigenesis (5,12).
In addition to MAPKs, other substrates have recently been
shown to be targets of VHR. These include the following:
1) the ErbB receptor of EGF2 in non-small cell lung cancers (24),
2) signal transducer and activator of transcription 5 (STAT5) in
immune cells stimulated by cytokines and/or growth factors
(19), and 3) focal adhesion kinase (FAK), with which VHR
plays a role in the formation and disassembly of focal adhe-
sions (25). Furthermore, VHR has been found to have a new
MAPK substrate-independent biological function that affects
the maintenance of genomic stability. Some authors (26,27)
recently suggested that many different nuclear proteins, such
as NBS1, NPM, NUCL, hnRNP C1/C2, and ATM/ATR, that
are directly or indirectly involved in different steps of the
DNA damage response and DNA repair pathways are very
likely to be substrates of VHR. These new putative protein
targets and functions of VHR will be discussed in the follow-
ing sections. We argue that this dual phosphatase constitutes a
potential candidate for pharmacological targeting in clinical
trials.
Biological functions of VHR/DUSP3 and its
association with human diseases
A high percentage of human cancers originate from one
or more activating mutations and/or genomic aberrations in
members of canonical signaling pathways, such as KRAS
and EGFR, that specifically activate the downstream MAPK
pathway (28). Furthermore, since VHR dephosphorylates
MAPK and growth factor receptors (i.e., HER2) (17,24), VHR
is relevant to the study of many types of cancers in which the
activities of these signaling pathways are altered. For example,
cervical cancer cell lines deficient in VHR arrest at the G1-S and
G2-M cell cycle transitions and therefore show massively
inhibited cell proliferation followed by initial signs of senes-
cence (17,18).
MAPK activation plays a growth-promoting role during
the early G1 phase of the cell cycle (17). Rahmouni et al. (17)
showed that differential VHR expression is coupled with cell
cycle transitions (i.e., high in the S, G2, and M phases) and
may regulate MAPK activity. They also showed that VHR
is expressed at low levels in early G1 phase, during which
cyclin D1 expression is required for cell cycle progression (29),
and that VHR is overexpressed in many types of cancers (30,31).
For example, in breast cancers, cyclin D1 expression was found
to be downregulated via a variety of mechanisms (32,33). One
of these mechanisms involves the VHR-mediated overexpres-
sion of BRCA1-IRIS (34,35), which is responsible for Cyclin D1
overexpression and the induction of cell proliferation. Addi-
tionally, overexpressing at least one of the components of the
BRCA1-IRIS/EGFR/ErbB2 axis reduced VHR expression in
normal and tumor breast cell lines, suggesting the develop-
ment of more aggressive endocrine-resistant breast cancer
phenotypes. Therefore, restoring VHR expression could poten-
tially rescue cyclin D1 overexpression-dependent cellular
transformation (35).
In non-small cell lung cancer (NSCLC) tissues, VHR expres-
sion and its activity against MAPKs were lower than those
observed in normal lung tissues, while VHR activity against
the ErbB2 receptor, which also regulates epithelial cell growth,
was increased (24). Wang et al. (24) demonstrated that VHR
can dephosphorylate a specific EGFR isoform in cell lines. The
EGFR-VHR interaction is weak, and the binding of the EGF
ligand to its receptor makes this interaction even weaker.
However, overexpressing VHR reduced the phosphorylation of
EGFR at Tyr-992 and made cells less responsive to EGF.
VHR overexpression suppressed cell proliferation in two-
or three-dimensional cultures of H1299 cells and reduced
the tumor sizes of xenografts. In addition, the mRNA and
protein levels of VHR were markedly lower in tumor tissues
than in adjacent healthy tissues in patients with non-small
cell lung cancers (24). Thus, decreasing VHR expression might
contribute to the initiation of lung cancer pathogenesis.
Wagner et al. proposed that the onset of lung tumorigenesis
in NSCLC involves the enhancement of ERK1/2 signaling as
a result of the epigenetic downregulation of VHR by KDM2A
demethylase (36). Some histone methylation modifiers, such
as KDM2A, are overexpressed in NSCLC and are important
for the tumorigenicity, proliferation, and invasiveness of these
cells (37). Depleting KDM2A reduced the number of cells in
S phase, inhibited their ability to form colonies in soft agar,
and, most interestingly, upregulated (by up to 9-fold) the
mRNA and protein expression levels of VHR. These data
suggest that the epigenetic repression of VHR activates the
downstream effects of ERK1/2 signal-mediated proliferation,
contributing to the invasive characteristics of NSCLC.
Studies have correlated VHR overexpression with the onset
or development of carcinogenic phenotypes. For example,
VHR levels were higher in human HeLa, SiHa, CaSki, C33,
and HT3 cell lines, which are derived from cervical tissues
and consist of epithelial cells representing various grades
of squamous carcinomas and adenocarcinomas, than in
primary cells and normal tissues (38). In cervical cancer
tissues, VHR is primarily enriched in nuclei. However, in
tumor cell lines, VHR is localized in both the cytoplasm and
nucleus, whereas in normal primary cells, it is exclusively
cytosolic (38). The enrichment of VHR in cell lines and
cervical cancer tissues is not due to increased gene or protein
expression or the stabilization of its mRNA. Instead, it cause
by an increase in the post-translational stabilization of the
VHR protein (38).
VHR is also enriched in prostate cancer tissues (39).
In normal prostate epithelial cells, androgen withdrawal led
to decreased cell proliferation, increased apoptosis, and
atrophy, whereas tumor prostate epithelial cells overcame
these deficiencies by shifting to an androgen-independent
state (40,41). When androgen-responsive prostate cancer cell
lines were treated with synthetic androgens, various MKPs
become overexpressed, including VHR. This changed was
correlated with the systematic dysregulation of MAPK signal-
ing observed during prostate carcinogenesis (42), as was
observed in LNCaP cells treated with TPA/thapsigargin plus
R1881. This dysregulation decreased JNK phosphorylation but
did not affect pERK expression levels (43,44). Androgen-sensitive
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grafts expressing VHR showed increased resistance to
castration-induced apoptosis, and tumor regression was
inversely correlated with VHR expression (39). One molec-
ular mechanism that has been suggested for inhibiting
prostate cancer progression is based on the finding that
VHR knockdown led to JNK activation and apoptosis,
suggesting potential therapeutic applications aimed at
targeting this phosphatase.
Finally, VHR is also overexpressed in dysplastic nevi (DN),
which are benign melanocytic tumors with a hyper-proliferative
phenotype (45). Very recently, VHR was found to interact
with and dephosphorylate FAK in H1299 cells and MEF/
lung epithelial cells. In VHR-null mice, these cells were more
migratory, and VHR overexpression decreased pFAK levels
and inhibited cell migration (25). The enhanced motility
phenotype observed in these cells supports the hypothesis
that the VHR phosphatase plays important roles in the develop-
ment of metastatic tumors.
It seems that with regard for the mechanisms underlying
tumorigenesis, this dual phosphatase plays two opposing
functions. Specifically, VHR knockdown inhibits the prolif-
eration and invasiveness of cancer cell lines, in accordance
with oncogene/oncoprotein models. However, in some
cellular contexts, VHR downregulation triggers hyper-
proliferation, migration and invasiveness in these cells. Thus,
it can also be considered a tumor suppressor (46).
Another VHR function associated with tumor onset,
establishment, growth, and maintenance is the regulation
of angiogenesis, which is a crucial step during tumorigenesis.
As shown previously in different types of cancers, endothe-
lial cells express higher than normal levels of VHR and other
MKPs, and this alteration was found to contribute to MAPK-
independent PKC-mediated tubulogenesis in vivo. In the
same FGF2-stimulated cells, VHR knockdown blocked angio-
genic sprouting. Finally, in different in vivo and ex vivomodels of
VHR-/- mice, neovascularization was clearly decreased (47).
Genomic instability is characteristic of a broad spectrum of
cancers, and genomic alterations can occur during any cell
division. These alterations or instabilities are minimized by
four major mechanisms: high-fidelity DNA replication during
S phase, precise chromosome segregation in M phase, accu-
rate and error-free repair of DNA damage, and a cell cycle
progression that is coordinated by cell cycle checkpoints (48).
Therefore, a disruption in any step in one or more of these
four mechanisms can lead to genomic instability and con-
tribute to cancer development.
In terms of MAPK signaling, with MAPKs the best character-
ized substrates of VHR, over-activating ERK1/2 induced multi-
polar spindles and aneuploidy in cells, while inhibiting ERK1/2
did not cause defects during chromosomal events such as the
spindle assembly checkpoint (SAC) and mitotic exit (49). The
role of this phosphatase in the formation of multipolar spindles
in cancer cells was recently investigated (50). In early mitotic
mammalian cells, both VHR and ERK1/2 localized to the
spindle apparatus (17,51), and transient VHR inhibition pro-
moted the formation of multipolar spindles in human mitotic
cells (50). These studies also demonstrated that depleting ERK1/2
activity but not JNK restored the multipolarity induced by a lack
of VHR and that overexpressing VHR reduced ERK1/2 phos-
phorylation by reversing multipolar spindles. These results
suggest that the VHR-mediated regulation of ERK1/2 plays
multiple roles in genomic stability (50).
Many of the nuclear events that control genomic stability
depend on high concentrations of proteins and/or rapid
cytoplasm-nucleoplasm translocation. Interestingly, VHR is
highly enriched in the nucleus of various cell lines (17,26,38,52),
especially after genotoxic stress (26). This may indicate that
this phosphatase has other substrates or that it has additional
roles in maintaining genomic stability that could be directly
or indirectly related to MAPK functions or other substrates.
In fact, recent studies using bioinformatics approaches and
validation analyses have suggested that novel VHR sub-
strates are involved in genomic stability (26). In one study,
the authors showed that VHR strongly co-localized with
phospho-H2AX (Ser139) in cells exposed to radiation-induced
DNA damage. They applied a bioinformatics analysis approach
to identify human nuclear proteins that could be putative VHR
substrates. Biochemical validation techniques were performed,
resulting in some very promising targets, such as pATM (S1981),
pATR (S428), pBRCA1 (S1423), BRCA2, CENP-F, Cyclin A,
NBS1, APE1, MRE11, RAD50, pCHK2 (T68), and pP53 (S15).
These results support the hypothesis that VHR is involved in
genomic maintenance and that its depletion decreases survival
and proliferation in human tumor cell lines by increasing DNA
damage and/or delaying or impairing DNA repair (52).
Previous authors have also employed mass spectrometry
to identify novel VHR substrates under cellular genotoxic
stress conditions (27). Among the proteins identified, half
were involved in mechanisms that control DNA and RNA
structures and functions. Based on the presence of phos-
phorylatable tyrosine residues and what is known of the
biological processes they regulate, experimental validation
studies performed using cellular and biochemical assays
suggested that nucleophosmin (NPM), nucleolin (NCL), and
heterogeneous ribonucleoprotein isoforms C1/C2 (hnRNP
C1/C2) are very likely to be VHR substrates (27). These
proteins are tyrosine-phosphorylated in vivo and in vitro and
could therefore be potential targets of dephosphorylation
by VHR, especially because they are involved in cell cycle
regulation and genomic instability (DNA damage response
and repair) processes (53-56). Thus, the phosphatase acti-
vity of VHR against these three proteins should be further
investigated.
VHR also mediates other signaling events in circulatory
system cells and blood-related diseases (57). The first such
studies were performed in resting T cells, which constitu-
tively express VHR. During resting, activating TCR did not
induce the expression of this enzyme via positive-feedback
mechanisms. In Tcells, VHR dephosphorylated MAPKs (espe-
cially JNK), but the UV radiation-induced activation of p38
was not targeted by VHR phosphatase activity (16). In Jurkat
T lymphocyte cells, VHR activity was regulated by ZAP-70,
a tyrosine kinase that phosphorylates VHR at Tyr138 (22).
Basal ZAP-70 activity was sufficient to stimulate T cells, but
under some circumstances, such as when IL-2 was used to
stimulate TCR, ZAP-70 activity induced more VHR-Tyr138
at the T-cell pole. These mechanisms regulated TCR and
induced signaling (22).
A TCR-related signaling pathway was also affected by
VHR in IFN-b-stimulated T and B cells via a mechanism
involving STAT5. STAT5 is phosphorylated by tyrosine
kinase 2 (TYK2). The Src homology 2 domain (SH2) of
STAT5 recognizes phospho-Tyr138 on VHR and brings these
domains together so that VHR can dephosphorylate STAT5.
However, in this signaling cascade, VHR does not regulate
the activity (via dephosphorylation) of other upstream
effectors of the pathway, such as Janus kinase 1 (JAK1) and
TYK2 (19).
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Another study showed that silencing VHR in Staphylococcus
aureus-infected human and murine macrophages increased the
production of pro-inflammatory cytokines via NF-kB signal-
ing. The phosphatase activity of VHR seemed to affect this
inflammatory response via a negative feedback component,
and the observed increase in cytokine levels may have been
responsible for the hyper-responsiveness observed in the
host immune system (58). In contrast to the pro-inflammatory
activities of VHR, VHR-deficient mice displayed tolerance to
LPS-induced endotoxic shock and polymicrobial septic shock.
A massive increase in anti-inflammatory M2-like macrophages,
decreased TNF production, and reduced ERK1/2 activity were
observed in these animals. In vivo, at eighteen hours after
endotoxic shock was induced by LPS, DUSP3-/- mice stabilize
their body temperature, while DUSP3+/+ mice remained
hypothermic. However, VHR knockout did not significantly
affect T and B lymphocytes, neutrophils, monocytes, or platelet
counts (59).
Additional studies have shown that VHR involvement in
the immune response to septic shock is dependent on sex
hormones produced by the host animals. Knocking out VHR
did not protect male mice from LPS-induced endotoxemia or
septic shock, and the percentage of M2-like macrophages
was lower in these mice than in VHR-/- female mice. The
body temperatures of all groups of mice were lower after
LPS injection (except in VHR-/- females), while resistance
to sepsis was associated with the decreased activation of
ERK1/2, PI3K, and AKT, suggesting phosphatase deficiency.
These data demonstrate that in the absence of VHR, female
sex hormones are very likely transcriptionally involved
in the acquired resistance of VHR-/- mice to LPS-induced
lethality (60).
Another very recent and important report provided mech-
anistic clues about the roles that VHR plays in platelet
aggregation (61,62). This phosphatase seems to be respon-
sible for reducing the levels of tyrosine phosphorylation of
the enzymes Syk and PLCg2, which regulate signaling via
collagen receptor glycoprotein VI (GPVI) and C-type lectin-
like type II (CLEC-2) receptors to promote aggregation in
a MAPK-independent manner. VHR knock-out mice exhib-
ited deficiencies in thrombus formation, suggesting that
VHR contributes to arterial thrombosis but is unnecessary
for primary hemostasis (61,62). The drugs currently used in
clinics to treat thrombosis usually cause unwanted side
effects, such as increasing the risk of gastrointestinal toxicity,
neutropenia, thrombocytopenia, and bleeding, in addition to
increasing the incidence of arterial thrombosis. Altogether,
these novel functions of VHR strongly support the notion
that this enzyme is a potential target for the development of
new therapies for platelet aggregation in circulatory system
cells and diseases (62).
VHR expression and patient survival
It has been shown that VHR gene expression and protein
levels are constitutively high in many different cell lines and
diverse tissues (38,39). The VHR protein is highly stable even
under high-stress conditions, such as cellular genotoxic or
oxidative pressure (26,52). VHR gene and protein expression
levels are not dependent on feedback regulation, such as that
associated with many other MKPs (1,5,8,63). However, most
VHR-inhibited cell lines exhibit phenotypes that are clearly
associated with cell cycle arrest, senescence, and reduced cell
survival even though VHR knock-out mice display a normal
phenotype and are free of apparent pathological features
(17,19,60,61).
However, one of the key remaining questions is that of
how VHR expression varies among patients carrying dif-
ferent types of cancer. By mining freely available databases
containing gene expression information related to human
cancers, it is possible to analyze, for example, correlations
between patient survival times and VHR expression. Using this
approach, we investigated the VHR gene at the BioProfiling.de
(64,65) website, which provides excellent assays that can be
used to examine the functions, interactions, and pathway
relationships of a single gene or a list of genes or to perform
clinical correlations to test a gene of interest as a biomarker or
to analyze its gene synergy (SynTarget tool) with relation to
cancer survival (PPISURV tool).
VHR-containing gene sets are available for 13 different
cancer types, including approximately 50 cancer subtypes or
clinical variables, in this web tool. To illustrate the potential
of this toolkit (and because these topics are very tightly
correlated with previously published cellular experiments),
we selected VHR gene expression and patient survival for
our analysis (64,65). As shown in Figure 1, positive survival
curves were observed when VHR was overexpressed in lung,
kidney, sarcoma, lymphoma, and breast cancer. All five
of these types of cancers have different GEO dataset IDs
(mostly obtained from TCGA, https://cancergenome.nih.gov/)
and clinical variables and are presented as data obtained
from different numbers of samples (ranging from 240 to 290).
The data showed that low VHR expression had a signifi-
cantly negative effect on patient survival. These results,
despite the fact that they are associative and predictive,
when analyzed in primary and immortalized cell lines derived
from the same tumor tissues, overall survival then was sub-
stantially lower in cells deficient in VHR than in control
cells (17,19,52,66).
However, as shown in Figure 2, VHR overexpression
resulted in negative survival curves in lung, brain, and breast
cancers. Although these cancers have different GEO dataset IDs,
are associated with different clinical variables, and originated
from a different numbers of samples (ranging from 115 to
450), high VHR expression had a statistically significant
negative effect on survival in all three cancer types. These
findings are in accordance with those presented in other
reports in the literature showing that in some cell lines and
tissues, VHR deficiency increases proliferation and survival
(24,35), while VHR overexpression leads to cell death (usually
by apoptosis).
An analysis of the correlations among the expression
profiles of the VHR gene in various human cancers, patient
survival times, and the cellular phenotypes related to VHR
loss or gain of function (LOF or GOF) experiments showed
that the biological functions of VHR seem to be tissue-
specific. Additionally, VHR behaves both positively and
negatively to regulate or mediate different types of human
diseases. Therefore, the dual-specificity phosphatase VHR,
similar to many other PTPs, has emerged as an attractive
drug target for future clinical interventions (11,12,62,67).
General and non-specific PTP inhibitors have long been
described in the literature, starting with sodium ortho-
vanadate (68), a-bromo-4-(carboxymethoxy)acetophenone (69),
phenylarsine oxide (70), and 4-hydroxy-3,3-dimethyl-
2H-benz[g]indole-2,5(3H)-dione (71). Although these have
been shown to be very potent inhibitory drugs, their low
selectivity makes them poor candidates for clinical trials.
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Because of the diversity of substrates and biological func-
tions attributed to VHR, which, as discussed in the previous
sections, can be easily extended to animal studies and pos-
sibly even to a clinical setting, a great deal of effort has been
made to identify specific VHR inhibitors. Once obtained,
these compounds should be tested in animal models and
humans. The results obtained in these studies will stimulate
the development of therapies aimed at leveraging the inhibi-
tion of VHR and/or other phosphatases in diseases where
the loss of VHR function may impair the proliferative capacity
of diseased cells (67). It is especially important to facilitate the
development of inhibitors that do not affect cellular processes
in surrounding healthy tissues.
Some potent pharmacological inhibitors of PTPs/DUSPs
are already in preparation for clinical trials, while others
have received a growing amount of attention in the last few
years. These include compounds that are usually obtained
(identified, isolated and purified) from natural sources, such
as plants, fungi, bacteria and seaweeds, and have high speci-
ficity for particular phosphatases (72). Additionally, very
Figure 2 - Survival curves generated using gene expression databases available at BioProfiling.de showing examples of different types
of cancer in which VHR overexpression was correlated with a reduction in patient survival times.
Figure 1 - Survival curves generated using gene expression databases available at BioProfiling.de showing examples of different types
of cancers in which VHR downregulation was correlated with a significant reduction in patient survival times.
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recently, an alternative to targeting DUSP enzymes at the
transcriptional level was presented by research into omega
3 fatty acids ingestion. For example, docosahexaenoic acid
(DHA) exerts a protective effect on mice brain development,
and when it was added to the diet (in mice) as DHA-
enriched fish-oil, it induced astroglial hyperactivation in a
dose-dependent manner that was mediated by glial fibrillary
acidic protein (GFAP) and dependent on increased MKP3
activity. This is the first evidence to show that natural
compounds obtained from natural sources can have potential
regulatory effects on PTPs/DUSPs during different cell biology
and tissue developmental processes and suggest the possibility
that they could be used to treat human pathologies (73).
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